RBCC Explores ‘Target-Rich Environment’ as Biotechnology Takes Over San
NOKOMIS, Fla. -- January 14, 2013
The executive leadership of Rainbow Coral Corp. (OTCBB: RBCC) has returned
from a business scouting trip to San Francisco with a thick stack of new
potential ventures to pursue.
The bay area became the biotechnology industry’s focus beginning last Monday
with Biotech Showcase 2013. OneMedForum SF 2013 and the J.P. Morgan 31st
Annual Healthcare Conference all descended on San Francisco at once. RBCC CEO
Patrick Brown said today that the company will begin sorting through the
dozens of new contacts that were made this week, searching for the most
promising new partnering opportunities available in the booming biotech space.
“San Francisco was undeniably a target-rich environment for a company like
ours, that helps brilliant innovators develop and commercialize their best
ideas,” he said. “The triple bill on the bay gave us a prime opportunity to
review the deal flow of new therapeutics and diagnostics currently being
readied for the marketplace. We’ll begin narrowing down our options to move
forward with the most promising of these biotech developers this week.”
As the Company searches for its next partner, RBCC’s biotech subsidiary
Rainbow Biosciences remains close to a joint venture deal with Amarantus
Bioscience, makers of exciting new diagnostic tools and therapies for
neurological diseases such as Parkinson’s.
Amarantus recently announced highly promising results in new animal trials of
its forthcoming Parkinson’s therapeutic, known as MANF.
For more information on RBCC and its biotechnology targets, please
Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories
Follow us on Twitter atwww.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The
Company continually seeks out new partnerships with biotechnology developers
to deliver profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please visit our
website atwww.rainbowbiosciences.com. For investment information and
performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.